Guggenheim analyst Yatin Suneja raised the firm’s price target on Celldex to $90 from $72 and keeps a Buy rating on the shares. Given barzolvolimab’s strong, consistent, and differentiated profile across multiple indications, the firm continues to view Celldex as “a leader in the mast cell space,” the analyst tells investors following the company’s Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLDX:
- Celldex Therapeutics’ New Regulation Risk – A Cause for Worry?
- Celldex expects cash to fund operations into 2026
- Celldex reports Q4 EPS (83c), consensus (74c)
- Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Celldex presents 12-week results from Barzolvolimab Phase 2 study in CSU
